GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBHMY) » Definitions » Cyclically Adjusted Price-to-FCF

Sino Biopharmaceutical (Sino Biopharmaceutical) Cyclically Adjusted Price-to-FCF : 13.33 (As of May. 24, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sino Biopharmaceutical Cyclically Adjusted Price-to-FCF?

As of today (2024-05-24), Sino Biopharmaceutical's current share price is $7.20. Sino Biopharmaceutical's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec23 was $0.54. Sino Biopharmaceutical's Cyclically Adjusted Price-to-FCF for today is 13.33.

The historical rank and industry rank for Sino Biopharmaceutical's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

SBHMY' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 11.7   Med: 55.69   Max: 108.13
Current: 14.39

During the past 13 years, Sino Biopharmaceutical's highest Cyclically Adjusted Price-to-FCF was 108.13. The lowest was 11.70. And the median was 55.69.

SBHMY's Cyclically Adjusted Price-to-FCF is ranked better than
92.23% of 103 companies
in the Biotechnology industry
Industry Median: 56.6 vs SBHMY: 14.39

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Sino Biopharmaceutical's adjusted free cash flow per share data of for the fiscal year that ended in Dec23 was $0.658. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.54 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sino Biopharmaceutical Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Sino Biopharmaceutical's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Cyclically Adjusted Price-to-FCF Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.14 54.44 34.55 25.36 17.09

Sino Biopharmaceutical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.55 - 25.36 - 17.09

Competitive Comparison of Sino Biopharmaceutical's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Sino Biopharmaceutical's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Cyclically Adjusted Price-to-FCF falls into.



Sino Biopharmaceutical Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Sino Biopharmaceutical's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=7.20/0.54
=13.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sino Biopharmaceutical's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec23 is calculated as:

For example, Sino Biopharmaceutical's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec23 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=0.658/117.2957*117.2957
=0.658

Current CPI (Dec23) = 117.2957.

Sino Biopharmaceutical Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 0.386 99.707 0.454
201512 0.149 102.015 0.171
201612 0.364 103.225 0.414
201712 0.413 104.984 0.461
201812 0.533 107.622 0.581
201912 0.544 110.700 0.576
202012 0.564 109.711 0.603
202112 0.565 112.349 0.590
202212 0.688 114.548 0.705
202312 0.658 117.296 0.658

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sino Biopharmaceutical  (OTCPK:SBHMY) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Sino Biopharmaceutical Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical (Sino Biopharmaceutical) Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (Sino Biopharmaceutical) Headlines

From GuruFocus

GuruFocus Value Idea Contest Sees 2 Winners!

By Holly LaFon Holly LaFon 07-12-2019

Matthews China Fund 3rd Quarter Commentary

By Holly LaFon Holly LaFon 10-19-2017

Matthews China Fund Comments on Sino Biopharmaceutical

By Sydnee Gatewood Sydnee Gatewood 10-25-2019

Matthews China Fund Comments on Sino Biopharmaceutical

By Sydnee Gatewood Sydnee Gatewood 01-28-2020

Matthews China Fund Comments on Sino Biopharmaceutical

By Vera Yuan Vera Yuan 10-20-2014

Value Idea Contest: Sino Biopharmaceutical

By Matthew Sipos Matthew Sipos 01-10-2019